The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Hyperinsulinemia Alters Myoinositol to d-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS
Abstract
Myoinositol (MI) and d-chiroinositol (DCI) are 2 stereoisomers and insulin sensitizers. Their physiological ratio differs from tissue to tissue, and they are regulated by an insulin-dependent epimerase whose activity is drastically reduced in conditions of insulin resistance. Based on literature data and on the fact that MI phospholipids are follicle-stimulating hormone (FSH) second messengers, we speculated that patients with polycystic ovary syndrome (PCOS) having hyperinsulinemia, present an enhanced MI to DCI epimerization in the ovary, leading to MI deficiency that impairs FSH signaling, resulting in reduced oocyte quality. In the present study, 20 patients with PCOS and 20 healthy women were enrolled for measurement of MI and DCI levels in their follicular fluid. Follicular fluid samples were taken using a vaginal probe and both MI and DCI were quantified analytically. Results showed that the ratio of MI-DCI dropped from 100:1 in healthy participants to 0.2:1 in patients with PCOS who additionally displayed significantly higher levels of insulin resistance, hyperinsulinemia, and luteinizing hormone. This study is the first one to analyze the misbalance in the MI-DCI ratio in the ovary of patients with PCOS, supporting the concept that maintaining the physiological levels of the 2 stereoisomers is crucial, in restoring the ovarian functionality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In women without PCOS, the ovarian MI:DCI ratio is 100:1, but in women with PCOS, the ratio is 0.2:1 (13).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [13]
Citations
Cites
1 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 2×
“MI-DCI ratio in the ovary, which might impair FSH signaling and worsen oocyte quality, as it has been shown by previously reported data.(24,35) Therefore, these new findings support the concept that a crucial factor for women with PCOS ovarian function is to maintain the physiological ovarian MI-DCI ratio.”
BackgroundResultRetracted(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Men at risk: occupation and male infertility.
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,219
Nestler, J. E., Jakubowicz, D. J., Falcon de Vargas, A., Brik, C., Quintero, N., & Medina, F. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4886 · Cited by 617
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518
Baillargeon, J.-P., Jakubowicz, D. J., Iuorno, M. J., Jakubowicz, S., & Nestler, J. E. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.02.127 · Cited by 300
D-Chiro-Inositol – Its Functional Role in Insulin Action and its Deficit in Insulin Resistance
Larner, J. (2002) · International Journal of Experimental Diabetes Research · doi:10.1080/15604280212528 · Cited by 279
Should all women with PCOS be treated for insulin resistance?
Marshall, J. C., & Dunaif, A. E. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.11.036 · Cited by 224
Rice, S., Christoforidis, N., Gadd, C., Nikolaou, D. S., Seyani, L., Donaldson, A., Margara, R. A., Hardy, K., & Franks, S. (2004) · Human Reproduction · doi:10.1093/humrep/deh609 · Cited by 224
Cited by
Sorted by citations
Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. E. (2017) · Endocrine Connections · doi:10.1530/ec-17-0243 · Cited by 220
Inositols in Insulin Signaling and Glucose Metabolism
Bevilacqua, A., & Bizzarri, M. (2018) · International Journal of Endocrinology · doi:10.1155/2018/1968450 · Cited by 192
Inositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154
Self-citationEffects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials
Unfer, V., Nestler, J. E., Kamenov, Z. A., Prapas, N., & Facchinetti, F. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1849162 · Cited by 151
Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach
Laganà, A. S., Garzon, S., Casarin, J., Franchi, M. P., & Ghezzi, F. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.09.001 · Cited by 178
Facchinetti, F., Bizzarri, M., Benvenga, S., D’Anna, R., Lanzone, A., Soulage, C. O., Renzo, G. C. D., Hod, M., Cavalli, P., Chiu, T. T. Y., et al. (2015) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2015.09.024 · Cited by 144
DiNicolantonio, J. J., & O’Keefe, J. H. (2022) · Open Heart · doi:10.1136/openhrt-2022-001989 · Cited by 105
Inositols in polycystic ovary syndrome: An overview on the advances
Facchinetti, F., Unfer, V., Dewailly, D., Kamenov, Z. A., Diamanti-Kandarakis, E., Laganà, A. S., Nestler, J. E., & Soulage, C. O. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.002 · Cited by 102
The latest reports and treatment methods on polycystic ovary syndrome
Stańczak, N. A., Grywalska, E., & Dudzińska, E. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2357737 · Cited by 161
Oxidative Stress and Male Fertility: Role of Antioxidants and Inositols
Luca, M. N. D., Colone, M., Gambioli, R., Stringaro, A., & Unfer, V. (2021) · Antioxidants · doi:10.3390/antiox10081283 · Cited by 101
Kamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100
“In patients with PCOS and insulin resistance, hyperinsulinemia induces higher DCI-to-MI ratio because of stimulated epimerase activity, which transforms MI to DCI [69].”
BackgroundBenelli, E., Del Ghianda, S., Di Cosmo, C., & Tonacchera, M. (2016) · International Journal of Endocrinology · doi:10.1155/2016/3204083 · Cited by 100
Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540578 · Cited by 94
Self-citationDinicola, S., Chiu, T. T. Y., Unfer, V., Carlomagno, G., & Bizzarri, M. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.362 · Cited by 97
Bevilacqua, A., Dragotto, J., Giuliani, A., & Bizzarri, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27623 · Cited by 85
Bevilacqua, A., Carlomagno, G., Gerli, S., Oliva, M. M., Devroey, P., Lanzone, A., Soulage, C. O., Facchinetti, F., Renzo, G. C. D., Bizzarri, M., et al. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1006616 · Cited by 87
Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol
Sacchi, S., Marinaro, F., Tondelli, D., Lui, J., Xella, S., Marsella, T., Tagliasacchi, D., Argento, C., Tirelli, A., Giulini, S., et al. (2016) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-016-0189-2 · Cited by 78
Inositol and human reproduction. From cellular metabolism to clinical use
Milewska, E. M., Czyzyk, A., Meczekalski, B., & Genazzani, A. D. (2016) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1188282 · Cited by 69
Monastra, G., Unfer, V., Harrath, A. H., & Bizzarri, M. (2016) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1247797 · Cited by 71
Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome
Unfer, V., & Porcaro, G. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.925795 · Cited by 68
Facchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63
Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis
Zeng, L., & Yang, K. (2018) · Endocrine · doi:10.1007/s12020-017-1442-y · Cited by 59
Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad762 · Cited by 70
“In women without PCOS, the ovarian MI:DCI ratio is 100:1, but in women with PCOS, the ratio is 0.2:1 (13).”
BackgroundInfluentialInositols’ Importance in the Improvement of the Endocrine–Metabolic Profile in PCOS
Wojciechowska, A., Osowski, A., Jóźwik, M., Górecki, R. J., Rynkiewicz, A., & Wojtkiewicz, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225787 · Cited by 64
Unfer, V., Kandaraki, E., Pkhaladze, L., Roseff, S., Vazquez-Levin, M. H., Laganà, A. S., Chan, S. Y., Yap‐Garcia, M. I. M., Greene, N. D. E., Soulage, C. O., et al. (2024) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2024.100159 · Cited by 58
Gateva, A., Unfer, V., & Kamenov, Z. A. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1421632 · Cited by 51
Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary
Roseff, S., & Montenegro, M. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6461254 · Cited by 52
Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS
Unfer, V., Dinicola, S., Laganà, A. S., & Bizzarri, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197157 · Cited by 51
Chukwuma, C. I., Ibrahim, M. A., & Islam, M. S. (2016) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-016-0517-1 · Cited by 49
Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols
Sortino, M. A., Salomone, S., Carruba, M. O., & Drago, F. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00341 · Cited by 50
Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART)
Facchinetti, F., Espinola, M. S. B., Dewailly, D., Özay, A. C., Prapas, N., Vazquez-Levin, M. H., Wdowiak, A., Unfer, V., Facchinetti, F., Unfer, V., et al. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.04.003 · Cited by 47
Inositols administration: further insights on their biological role
Coldebella, D., Buzzaccarini, G., Ferrari, J., Sleiman, Z., D’Alterio, M. N., Corte, L. D., Cucinella, G., & Gullo, G. (2022) · Italian Journal of Gynaecology and Obstetrics · doi:10.36129/jog.2022.40 · Cited by 44
Physiological role and clinical utility of inositols in polycystic ovary syndrome
Bevilacqua, A., & Bizzarri, M. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.03.007 · Cited by 42
Myo-inositol in assisted reproductive technology from bench to bedside
Etrusco, A., Laganà, A. S., Chiàntera, V., Buzzaccarini, G., & Unfer, V. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.09.005 · Cited by 45
Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review
Bizzarri, M., Monti, N., Piombarolo, A., Angeloni, A., & Verna, R. (2023) · Nutrients · doi:10.3390/nu15081875 · Cited by 50
Michell, R. H. (2018) · British Journal Of Nutrition · doi:10.1017/s0007114518000946 · Cited by 35
Garzon, S., Laganà, A. S., & Monastra, G. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1651839 · Cited by 32
Bevilacqua, A., Dragotto, J., Lucarelli, M., Emidio, G. D., Monastra, G., & Tatone, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115691 · Cited by 32
Facchinetti, F., Dante, G., & Neri, I. (2015) · ISGE series · doi:10.1007/978-3-319-23865-4_13 · Cited by 30
Moslehi, N., Zeraattalab-Motlagh, S., Rahimi Sakak, F., Shab-Bidar, S., Tehrani, F. R., & Mirmiran, P. (2023) · Nutrition Reviews · doi:10.1093/nutrit/nuac075 · Cited by 28
Zhang, J., Xing, C., Zhao, H., & He, B. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.1926975 · Cited by 28
Mohammadi, S., Eini, F., Bazarganipour, F., Taghavi, S. A., & Azizi, M. (2021) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00741-0 · Cited by 30
Dietary supplements for polycystic ovary syndrome
Kiani, A. K., Donato, K., Dhuli, K., Stuppia, L., & Bertelli, M. (2022) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2022.63.2s3.2762 · Cited by 26
Inositols in the ovaries: activities and potential therapeutic applications
Laganà, A. S., Forte, G., Bizzarri, M., Kamenov, Z. A., Bianco, B. A. V., Kaya, C., Gitas, G., Alkatout, İ., Terzić, M., & Unfer, V. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2071259 · Cited by 25
Does myo-inositol effect on PCOS follicles involve cytoskeleton regulation?
Bizzarri, M., Cucina, A., Dinicola, S., Harrath, A. H., Alwasel, S. H., Unfer, V., & Bevilacqua, A. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.03.014 · Cited by 25
New clinical targets of d -chiro-inositol: rationale and potential applications
Laganà, A. S., Garzon, S., & Unfer, V. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1785429 · Cited by 23
Monastra, G., Vučenik, I., Harrath, A. H., Alwasel, S. H., Kamenov, Z. A., Laganà, A. S., Monti, N., Fedeli, V., & Bizzarri, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.660381 · Cited by 23
The Role of Inositols in the Hyperandrogenic Phenotypes of PCOS: A Re-Reading of Larner’s Results
Fedeli, V., Catizone, A., Querqui, A., Unfer, V., & Bizzarri, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076296 · Cited by 24
Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients
Petrillo, T., Semprini, E., Tomatis, V., Arnesano, M., Ambrosetti, F., Battipaglia, C., Sponzilli, A., Ricciardiello, F., Genazzani, A. R., & Genazzani, A. D. (2022) · Biomedicines · doi:10.3390/biomedicines10081924 · Cited by 18
Lete, I., Martínez, A., Lasaga, I., Centurión, E., & Vesga, A. (2024) · Gynecological Endocrinology · doi:10.1080/09513590.2023.2301554 · Cited by 18
Fedeli, V., Unfer, V., Dinicola, S., Laganà, A. S., Canipari, R., Monti, N., Querqui, A., Galante, E., Laurenzi, G., & Bizzarri, M. (2024) · Cells · doi:10.3390/cells13141171 · Cited by 18
Santoro, M., Aquila, S., & Russo, G. (2020) · Systems Biology in Reproductive Medicine · doi:10.1080/19396368.2020.1826067 · Cited by 17
Pustotina, O. A., Myers, S. H., Unfer, V., & Rasulova, I. (2024) · Gynecologic and Obstetric Investigation · doi:10.1159/000536163 · Cited by 21
Long-Lasting Therapies with High Doses of D-chiro-inositol: The Downside
Nordio, M., Espinola, M. S. B., Bilotta, G., Capoccia, E., & Oliva, M. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010390 · Cited by 17
Treatment with Myo-Inositol Does Not Improve the Clinical Features in All PCOS Phenotypes
Unfer, V., Russo, M., Aragona, C., Bilotta, G., Oliva, M. M., & Bizzarri, M. (2023) · Biomedicines · doi:10.3390/biomedicines11061759 · Cited by 14
Inositols: from physiology to rational therapy in gynecological clinical practice
Unfer, V., Orrù, B., & Monastra, G. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1225039 · Cited by 13
Pharmacologic Treatment of Polycystic Ovary Syndrome: Alternate and Future Paths
Legro, R. S., & Martel‐Duguech, L. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1603729 · Cited by 11
Cutler, D. A., Shaw, A. K., Pride, S. M., Bedaiwy, M. A., & Cheung, A. P. (2018) · Trials · doi:10.1186/s13063-018-3009-5 · Cited by 12
Does inositol ratio orchestrate the fate of ovarian follicles?
Unfer, V., & Forte, G. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109983 · Cited by 12
Xia, J., Tian, W., Yin, G., & Yan, H. (2019) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12008 · Cited by 11
Effects of myo-inositol plus folic acid on ovarian morphology and oocyte quality in PCOS mouse model
Haghighi, M., Mehdizadeh, M., Amjadi, F., Zandieh, Z., Najafi, M., Artimani, T., Mohammadi, F., & Mehdizadeh, R. (2023) · Zygote · doi:10.1017/s0967199422000557 · Cited by 10
Myo-inositol: therapeutic possibilities and pregravid preparation in women with pcos
Kaluginа, L. V., & Юско, Т. И. (2018) · Reproductive Endocrinology · doi:10.18370/2309-4117.2018.42.40-45 · Cited by 10
Dinicola, S., Unfer, V., Soulage, C. O., Yap‐Garcia, M. I. M., Bevilacqua, A., Benvenga, S., Barbaro, D., Wdowiak, A., Nordio, M., Dewailly, D., et al. (2024) · Gynecologic and Obstetric Investigation · doi:10.1159/000536081 · Cited by 9
Physiological and pathophysiological roles of inositols
Monastra, G., Dinicola, S., & Unfer, V. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91673-8.00008-x · Cited by 7
An innovative approach to polycystic ovary syndrome
Bizzarri, M., Logoteta, P., Monastra, G., & Laganà, A. S. (2021) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2021.1920006 · Cited by 7
Moretti, C., Bonomi, M., Dionese, P., Federici, S., Fulghesu, A. M., Giannelli, J., Giordano, R., Guccione, L., Maseroli, E., Moghetti, P., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02363-w · Cited by 9
Almalki, W. H. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04123-3 · Cited by 5
Cutler, D. A. (2019) · cIRcle (University of British Columbia) · doi:10.14288/1.0378929 · Cited by 5
Zhang, Y., Shi, B., Tian, Y., XU, S., & Chang, H. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1697275 · Cited by 4
D‐Chiro‐Inositol and LPS Induce a PCOS‐Like Hyperandrogenic Response in Human KGN Granulosa Cells
Giuliani, C., Casoli, G., Emidio, G. D., Tatone, C., & Bevilacqua, A. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70779 · Cited by 4
Use of Inositols in Polycystic Ovary Syndrome
Pustotina, O. A. (2020) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2020-16-28-24-34 · Cited by 5
Kitaya, K., Takaya, Y., Nishiyama, R., Yamaguchi, K., Matsubayashi, H., Takeuchi, T., Mizuta, S., & Ishikawa, T. (2019) · Clinical and Experimental Obstetrics & Gynecology · doi:10.12891/ceog4567.2019 · Cited by 4
The role of myo-inositol supplement in assisted reproductive techniques
Bashiri, Z., Sheibak, N., Amjadi, F., & Zandieh, Z. (2022) · Human Fertility · doi:10.1080/14647273.2022.2073273 · Cited by 6
Animal models of polycystic ovary syndrome
Kulkarni, S., Dahake, D., Gupta, K., Rathod, K., Aswar, U. M., & Thareja, S. (2025) · Systems Biology in Reproductive Medicine · doi:10.1080/19396368.2025.2551005 · Cited by 3
Mertoğlu, C., Günay, M., Gül, V., Külhan, M., Aktaş, M., & Çoban, T. A. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1409710 · Cited by 3
Probabilistic guided polycystic ovary syndrome recognition using learned quality kernel
He, D., Liu, L., Miao, S., Tong, X., & Sheng, M. (2019) · Journal of Visual Communication and Image Representation · doi:10.1016/j.jvcir.2019.102587 · Cited by 3
Евгеньевна, Ч. Г., & Алексеевна, П. В. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-087 · Cited by 3
Kalem, M. N., Kalem, Z., & Gürgan, T. (2016) · Gynecology Obstetrics and Reproductive Medicine · doi:10.21613/gorm.2016.54 · Cited by 3
Myo-inositol: with or without [Letter to the Editor]
Carlomagno, G., Unfer, V., Benvenga, S., & Nestler, J. E. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej14-0566 · Cited by 3
Duan, M., Yang, M., Li, C., Wu, X. F., Yin, X., & Zhu, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1741509 · Cited by 2
Сергеевна, А. О., Юрьевна, П. В., & Krylova, E. (2021) · V F Snegirev Archives of Obstetrics and Gynecology · doi:10.17816/2313-8726-2021-8-2-81-92 · Cited by 2
On the therapy for polycystic ovary syndrome
Unfer, V., & Monastra, G. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_409_17 · Cited by 2
Looking at the Link between Diet and PCOS Onset and Management
Porcaro, G. (2016) · Journal of Nutritional Health & Food Science · doi:10.15226/jnhfs.2016.00178 · Cited by 2
New possibilities of correction of metabolic disorders in women with PCOS
Kaluginа, L. V., & Татарчук, Т. Ф. (2018) · Reproductive Endocrinology · doi:10.18370/2309-4117.2018.39.27-32 · Cited by 2
FIRAT, S., & Fisunoğlu, M. (2021) · Akdeniz Medical Journal · doi:10.53394/akd.958775 · Cited by 1
Thirumurugan, A., Ravi, S., & Annamalai, A. (2026) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2026.107088 · Cited by 1
Use of myo-inositol in the treatment of PCOS symptoms in adolescents
Pkhaladze, L., Unfer, V., & Dewailly, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91673-8.00001-7 · Cited by 2
Supplementation with d-chiro-inositol in women
Laganà, A. S., Aragona, C., & Prapas, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91673-8.00004-2 · Cited by 1
Inflammation in Pregnant Women with Obesity and Gestational Diabetes Mellitus
Kim, T. S. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-39721-9_9 · Cited by 1
Pregravid preparation of women with polycystic ovary syndrome.
Ісламова, Г. О. (2020) · Reproductive Endocrinology · doi:10.18370/2309-4117.2020.53.30-34 · Cited by 1
Prise en charge de l’infertilité chez la femme obèse
Vincentelli, C., Gaborit, B., Castera, V., Dutour, A., & Courbière, B. (2017) · Obésité · doi:10.1007/s11690-017-0559-8
Malvi, A., Chaturvedi, A., Mehta, S. V., Sonkusare, K., & Dave, N. (2019) · The New Indian Journal of OBGYN · doi:10.21276/obgyn.2019.5.2.2
Diet, Nutritional Supplements, and Botanical Medicine in Polycystic Ovary Syndrome
Lucius, K. (2021) · Alternative and Complementary Therapies · doi:10.1089/act.2021.29356.klu
Role of Insulin-Sensitizing Drugs in PCOS Management
Kojok, D., Ghazeeri, G. S., & Awwad, J. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_12 · Cited by 1
Nestler, J. E., & Laganà, A. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-45534-1_16
Therapeutic options for pre-gravidary training in women with a history of combined infertility
Туманова, Л. Е., & Kolomiets, E. V. (2022) · Reproductive health of woman · doi:10.30841/2708-8731.2.2022.261808
Treatments with inositols in IVF procedures
Espinola, M. S. B., Wdowiak, A., & Yu, T. C. T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91673-8.00015-7
Overcoming inositol resistance
Kamenov, Z. A., & Oliva, M. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91673-8.00009-1
دراسة مدى انتشار ومصادر متلازمة تكيس المبايض في عينة من النساء المصابات بالعقم بمنطقة براك الشاطئ
الزيداني, غ. م., يونس, م. ا., & اشناف, ا. م. ع. (2022) · Journal of Pure & Applied Sciences · doi:10.51984/jopas.v21i3.2028
Effects of inositols in menstrual cycle regulation in adolescent girls with ovarian dysfunction
Uvarova, E. V., Turchinets, A. I., Kumykova, Z. K., Khaschenko, E. P., Mamedova, F. S., & Ivanets, T. Y. (2023) · Pediatric and Adolescent Reproductive Health · doi:10.33029/1816-2134-2023-19-1-26-35
Metadata
- Authors
- Unfer, V., Carlomagno, G., Papaleo, E., Vailati, S., Candiani, M., & Baillargeon, J.-P.
- Affiliations
- Agunco (IT)
- IRCCS Ospedale San Raffaele (IT)
- Université de Sherbrooke (CA)
- Corresponding author
- Carlomagno, Gianfranco
- Venue
- Reproductive Sciences
- Published
- 2014-07
- Volume
- 21
- Issue
- 7
- Pages
- 854-858
- ISSN
- 1933-7191 (ISSN-L)
- 1933-7205
- OpenAlex
- W2106706873
- Cited by
- 105
- References
- 37
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 8 · 2023: 16 · 2022: 10 · 2021: 11 · 2020: 11 · 2019: 8 · 2018: 9 · 2017: 7 · 2016: 11 · 2015: 4 · 2014: 2
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Reproductive Sciences (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- polycystic ovary syndrome, hyperinsulinemia, myo-inositol, follicular fluid, insulin resistance, epimerase, oocyte quality, luteinizing hormone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
